Purpose Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC).
Introduction
Approximately 20% of breast cancers (BC) overexpress the human epidermal growth factor receptor 2 (HER2), with this aberration associated with a poor prognosis [1] . The introduction of trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of HER2, has significantly improved longer-term outcomes in patients with HER2-positive BC and changed the natural history of this disease [2] [3] [4] .
The development of several new agents against HER2-positive disease such as monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates have led to an abundance of therapeutic choices for these patients [5] . Moreover, the dual HER2 blockade has been established in the metastatic setting confirming the preclinical evidence of enhanced HER2 inhibition [6, 7] . Current recommendations suggest the use of trastuzumab (plus pertuzumab if available) either with combination but mainly with single-agent chemotherapy for patients with metastatic BC [8] . Further refinement of the companion cytotoxics to be coupled with HER2 blockade is needed.
The CMF combination consisting of cyclophosphamide (C), methotrexate (M), and 5-fluorouracil (5-FU) has been used in various dose and administration schedules. The classical regimen is the oral Bonadonna CMF (cyclophosphamide 100 mg/m2 orally days 1-14; methotrexate 40 mg/m2 IV days 1 and 8; and 5-fluorouracil 600 mg/m2 IV days 1 and 8 every 4 weeks) which constitutes one of the first efficacious chemotherapy regimens, introduced more than 40 years ago, used in both the adjuvant and metastatic settings [9] [10] [11] [12] . As there is continuing interest for new trastuzumab-chemotherapy combinations, we sought to investigate this regimen in the metastatic setting.
The ErbB2 (HER2) gene product is composed of a cytoplasmic domain, which has a tyrosine kinase activity, a transmembrane domain, and an extracellular domain (ECD). The ECD can be cleaved and shed from the surface of BC cells and its levels can be detected in serum samples. Serum-shed antigen can be detected in a proportion of 15-30% of patients with HER2-positive MBC and could be used as biomarker not only to detect disease recurrence or progression but also predict response to the treatment [13] .
Here, we report the results of the EORTC 10995 study designed to assess the cardiac events and efficacy observed during treatment with CMF plus or without trastuzumab in patients with HER2-positive MBC. We additionally report for a proportion of patients, the associations of serum levels of HER2-shed antigen prior to each treatment cycle with clinical efficacy.
Patients and methods
Women aged ≥18 years of any menopausal status, with histologically or cytologically proven previously treated MBC, centrally confirmed as overexpressing HER2 {3+ or 2+ by HercepTest™ and positive by fluorescent in situ hybridization (FISH)} and measurable disease (per RECIST 1.0) were included (Fig. 1 , Suppl. App. Par 1 & 2) . Ethical committees of all participating sites (17 sites in 10 countries) approved the study. All patients signed informed consent.
Treatment
Treatment cycles in both arms were reported every 4 weeks and the CMF was administered either as in the classical Bonadonna regimen (described above) or as a modified regimen differing from the classical Bonadonna regimen only in the way the cyclophosphamide was administered, i. e., 600 mg/m 2 given IV on days 1 and 8 for 8 cycles. In the CMF+trastuzumab arm, patients received maximally 8 cycles and in case of benefit continued treatment with trastuzumab monotherapy (q3 weeks at 6 mg/kg) until disease progression (Suppl. App. Par. 2).
Protocol revision
The growing body of evidence supporting the activity of trastuzumab in combination with other cytotoxics for HER2-positive MBC led to a major amendment in August 2003, where the CMF-alone arm was dropped and the trial continued as a single-arm study with only the CMF+ trastuzumab arm, using the same statistical design as originally planned (Suppl. App. Par. 3).
Study endpoints

Cardiac safety
Cardiac toxicity was defined as symptomatic congestive heart failure (CHF) (Table 1S, Suppl. App.), or decline in LVEF of ≥15% (absolute percentage points) from baseline, or any decline in LVEF to a value ≥5% (absolute percentage points) below the lower limit of normal for the institution. CHF was graded using the New York Heart Association (NYHA) criteria and subsequent management was at the investigator's discretion. At entry, the presence of any cardiac risk factors (e.g., smoking history, hypertension, hyperlipidemia, diabetes, etc.) was documented. Cardiac monitoring started with a LVEF baseline measurement (by echocardiography or multiple gated acquisition) followed by LVEF measurements every 3 months using the same technique until disease progression. Additional unscheduled measurements were required in patients who developed CHF as well as a repeat measurement 2 weeks after demonstration of a decline in LVEF, regardless of symptoms, in order to confirm the drop. Trastuzumab was discontinued if the LVEF drop was confirmed, and in patients who developed symptomatic CHF.
Efficacy
Efficacy was measured by the objective response rate (ORR) according to RECIST 1.0. Objective response was defined as partial or complete response (PR and CR) confirmed at least 4 weeks after first documentation. During the first 8 cycles, radiological tumor assessments were performed every two cycles and then every two months until progression. Analysis of RR was based on investigator assessment of the best response after start of the treatment.
Serum HER2-ECD-shed antigen
A proportion of patients participated in the translational research substudy, where a serum sample was collected before each cycle of CMF and/or trastuzumab. For this analysis, serum HER2-ECD-shed antigen status was determined in serum samples with the Immuno-1 immunoassay for HER2 (Bayer Corporation, Tarrytown, NY). This assay is an ELISA with two monoclonal antibodies against the ECD of the HER2 and has been approved by the FDA as accurate and reliable assay for longitudinal monitoring of shed HER2. The upper end of the normal range was defined at 15 ng/ml (2-15 ng/ml) [13, 14] .
Statistical Analyses
This study started in 2002 as a randomized non-comparative phase II trial between CMF alone, and CMF +trastuzumab (both during CMF and after CMF) with 2 co-primary endpoints: ORR and cardiac toxicity (CHF), using a 2-stage Bryant and Day design [15] . The null hypothesis for the experimental arm was set at a RR of 15% and a CHF rate of 15%. The trial was designed to have 90% power to detect a RR of 35% or more, and a CHF rate of 5% or less also with 90% power. As per the analysis plan, the co-primary endpoints of RR and cardiac toxicity were analyzed on all treated patients. Secondary endpoints were duration of response, time to progression (TTP), toxicity, progression-free survival (PFS), and overall survival (OS). Safety and treatment information were summarized for all treated patients. All efficacy analyses other than RR were performed on the per protocol population (treated eligible patients). After the drop of the CMF-alone arm, the trial continued as a non-randomized trial with only the CMF+trastuzumab arm, using the same statistical design for this experimental regimen as originally planned (Suppl. App. Par. 3).
Results
Between March 2002 and January 2006, 90 patients were enrolled. The cut-off date for this analysis was February 4, 2008; the median follow-up was 44 months. In total, 19 patients were enrolled into the CMF-only arm when it was prematurely closed in 2003. A total of 71 patients were enrolled in the CMF+trastuzumab arm, (Fig. 1) . The main baseline patients' characteristics are summarized in Table 1 . Treatment compliance and treatment discontinuation reasons in both arms and in the maintenance phase are provided in Tables 2S & 3S (Suppl. App.).
Safety (cardiac and non-cardiac)
During the study, 13 (18%) patients who received trastuzumab (in combination with CMF and as maintenance) had a per protocol absolute LVEF decrease. Nine out of 37 patients with cardiac risk factors had a LVEF drop as compared to 4 out of 33 patients without cardiac risk factors. Their median baseline LVEF was 61.5% (52-84.8%) and the median time to occurrence of LVEF drop was 35 weeks (any decline ≥5% below normal per institutional standards) and 16 weeks (≥15% decline from baseline). There was no difference in the LVEF change in average depending on whether or not patients had prior exposure to anthracycline (Fig. 2) . Three patients developed CHF: one grade 1 (asymptomatic detected by LVEF measurement), one grade 2, and one grade 3 per NYHA classification (details; Suppl. App. Par. 6). All three patients had cardiac risk factors, but only the two patients with ≥grade 2 CHF had prior anthracycline exposure. None of the patients developed CHF while on CMF-only arm.
In both arms, the most frequent AEs (per CTCAE v 2.0) were anemia and leukopenia. In the CMF-only arm, no patient stopped the treatment due to toxicity. Ten patients in CMF+trastuzumab and three in trastuzumab monotherapy stopped due to toxicity (Suppl. App. Table 4S ).
Efficacy
In total, 35 out of 70 patients treated with CMF+-trastuzumab had an OR (8 CR and 27 PR) and 6 out of 19 patients treated with CMF alone had an OR (5 PR and 1 CR), resulting in ORR of 50% (95% CI 38-62%) and 32% (95% CI 13-57%) respectively. The median duration of response was 10.3 months (95% CI 7.9-12.9 months) for CMF+trastuzumab and 5.4 months (95% CI 3.7-11.8 months) for CMF. In addition, 13 patients had stable disease as best response in the CMF+trastuzumab arm and one in the CMF arm. Patients treated with CMF +trastuzumab had a median PFS of 9.4 months (95% CI 8.1-11.6 months) with a 1-year OS of 82% (95% CI 70-89%) and median OS of 24.5 months (95% CI 16.8-51.1) and for those treated with CMF the median PFS was 4.8 months (95% CI 2.8-7.9 months) with a 1-year OS of 79% (95% CI 53-92%) and median OS of 19.25 (95% CI 16.8-51.1 months) for CMF (Fig. 3) . The final per protocol conclusion was that the null hypothesis could be rejected in favor of a higher RR, combined with a low CHF rate.
ECD-shed antigen
Serial serum samples were available from 45 patients among 90 patients (50%) recruited in the study: 37 (82.2%) patients from the CMF+trastuzumab arm, and 8 (17.8%) from the CMF-only arm (Suppl. App. Par. 7). The analysis was performed in two laboratories (Roche and an academic). The median value of the 33 patients analyzed in the Roche laboratory was 61.1 ng/ml (range 13.6-2875.6 ng/ ml), while the median value for the 12 patients analyzed by the academic laboratory was 53.3 ng/ml (range 6.9-380.0 ng/ml). No significant differences (Mann-Whitney test, p = 0.4) between laboratories were observed suggesting that variability between the two laboratories does not affect the results.
Patients with detectable (range 6.9-2875.6 ng/ml) baseline serum ECD-shed antigen showed a significantly worse 1-year PFS at 17.8% as compared to 42.2% (p = 0.036) for those without detectable serum-shed antigen, Fig. 4) . We then investigated whether the serum ECDshed antigen increment from baseline predicts for tumor progression according RECIST evaluation. As the absolute serum ECD-shed antigen values were highly variable between patients, the percent of change from baseline was used instead of the absolute value to detect a biochemical signal (i.e., a Δ% increment from nadir). As such, the possible differences between the two labs were somewhat mitigated. A detailed description of selection of the threshold is available in the Suppl. App. Par. 7. In brief, when considering different levels of increment from the nadir (10, 20, 30, 40 and 50%), in patients with a 30% increase in serum ECD-shed antigen during treatment, an estimated 95% of the patients progressed within 3 months and 100% progressed within 6 months.
Discussion
In this study, the combination of the first-generation chemotherapy regimen of CMF plus trastuzumab resulted in incidences of cardiac events and LVEF reduction rates within the previously reported ranges [16] [17] [18] [19] . For the patients who experienced reduction in LVEF, cardiac risk factors did not appear to have a predictive value; however, the three patients who developed CHF had cardiac risk factors; of note, predictive biomarkers identifying patients who will develop cardiac toxicity due to trastuzumabcombined chemotherapy are actively sought [20] . Concerning non-cardiac toxicities, the regimen was well tolerated with hematologic toxicities being the main safety issue but consistent with previously conducted studies with CMF [12, 21] .
In terms of efficacy, CMF+T resulted in higher PFS and OS than did CMF alone in line with the results from other studies which tested the combination of various chemotherapeutic agents with trastuzumab [22] . Maintaining HER2 blockade during all stages of metastatic HER2-positive MBC with different chemotherapy backbones constitutes a standard approach [23] . Therefore, since the development of anti-HER2 therapies has improved the survival of these patients, the options of chemotherapeutic agents with which these targeted agents can be combined should be actively sought [22] . CMF is a regimen which has proven efficacy in earlier stages of the disease, as demonstrated by the neoadjuvant NOAH study, where the combination of CMF plus trastuzumab resulted in 38% pathologic complete response in breast and axilla [24] . Notwithstanding the late reporting of these results, they add valuable data to the existing literature identifying yet another potent chemotherapy backbone that can be coupled with trastuzumab in the metastatic setting supporting the combination of alkylators/platinum agents with trastuzumab [25] .
Additionally, patients with increasing serum-shed antigen values both at diagnosis and over time are at considerably higher risk of earlier progression than those without this signal; in particular, the risk of progression is higher at least 30% increase with an absolute value of marker ≥15 ng/ml. Several authors have already reported that relapse rates were significantly higher in those patients that had elevated levels of serum-shed antigen (≥15 ng/ml) levels at baseline and subsequent PFS was predicted by early changes, suggesting that alterations could be useful in monitoring disease and predicting disease outcome [26] .
These findings are consistent with other reports supporting the conclusion that serum ECD-shed antigen may constitute a useful method of monitoring patients receiving trastuzumab-based therapy.
The study has limitations, as it was designed from the beginning as a non-comparative phase II randomized study which by definition did not aim to compare treatment and cardiac safety outcomes in the two treatment arms. However, due to rapid development of trastuzumab in HER2-positive disease, a proper comparison between CMF with or without trastuzumab would not have been feasible and the data generated are sufficient to suggest an alternative chemotherapy backbone with anti-HER2 blockade especially in the era of newer anti-HER2 agents which have enriched our therapeutic armamentarium for this otherwise aggressive subtype of breast cancer.
We conclude that the combination of CMF plus trastuzumab represents a safe and active treatment option for patients with HER2-positive MBC when other options are Fig. 4 Rates of PFS at 1-year in patients with and without detectable rates of serum ECD shed antigens
